456 related articles for article (PubMed ID: 29282690)
1. Targeting the Epigenome as a Novel Therapeutic Approach for Breast Cancer.
Oh S; Ko JY; Oh C; Yoo KH
Adv Exp Med Biol; 2017; 1026():287-313. PubMed ID: 29282690
[TBL] [Abstract][Full Text] [Related]
2. Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.
Falahi F; van Kruchten M; Martinet N; Hospers GA; Rots MG
Breast Cancer Res; 2014 Jul; 16(4):412. PubMed ID: 25410383
[TBL] [Abstract][Full Text] [Related]
3. Human DNA (cytosine-5)-methyltransferases: a functional and structural perspective for epigenetic cancer therapy.
Rondelet G; Wouters J
Biochimie; 2017 Aug; 139():137-147. PubMed ID: 28600135
[TBL] [Abstract][Full Text] [Related]
4. [Targeted epigenetic therapy of cancer. Achievements and perspectives].
Valdespino-Gómez VM; Valdespino-Castillo VE
Cir Cir; 2012; 80(5):470-80. PubMed ID: 23351455
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic regulation of gene expression as an anticancer drug target.
Ferguson LR; Tatham AL; Lin Z; Denny WA
Curr Cancer Drug Targets; 2011 Feb; 11(2):199-212. PubMed ID: 21158714
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic mechanisms of breast cancer: an update of the current knowledge.
Karsli-Ceppioglu S; Dagdemir A; Judes G; Ngollo M; Penault-Llorca F; Pajon A; Bignon YJ; Bernard-Gallon D
Epigenomics; 2014; 6(6):651-64. PubMed ID: 25531258
[TBL] [Abstract][Full Text] [Related]
7. Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer.
Damaskos C; Garmpis N; Valsami S; Kontos M; Spartalis E; Kalampokas T; Kalampokas E; Athanasiou A; Moris D; Daskalopoulou A; Davakis S; Tsourouflis G; Kontzoglou K; Perrea D; Nikiteas N; Dimitroulis D
Anticancer Res; 2017 Jan; 37(1):35-46. PubMed ID: 28011471
[TBL] [Abstract][Full Text] [Related]
8. (-)-Epigallocatechin-3-gallate reverses the expression of various tumor-suppressor genes by inhibiting DNA methyltransferases and histone deacetylases in human cervical cancer cells.
Khan MA; Hussain A; Sundaram MK; Alalami U; Gunasekera D; Ramesh L; Hamza A; Quraishi U
Oncol Rep; 2015 Apr; 33(4):1976-84. PubMed ID: 25682960
[TBL] [Abstract][Full Text] [Related]
9. Epigenetics and cancer treatment.
Kristensen LS; Nielsen HM; Hansen LL
Eur J Pharmacol; 2009 Dec; 625(1-3):131-42. PubMed ID: 19836388
[TBL] [Abstract][Full Text] [Related]
10. Genistein Induces Alterations of Epigenetic Modulatory Signatures in Human Cervical Cancer Cells.
Sundaram MK; Ansari MZ; Al Mutery A; Ashraf M; Nasab R; Rai S; Rais N; Hussain A
Anticancer Agents Med Chem; 2018; 18(3):412-421. PubMed ID: 28925878
[TBL] [Abstract][Full Text] [Related]
11. Epigenetics of Breast Cancer: Clinical Status of Epi-drugs and Phytochemicals.
Shukla S; Penta D; Mondal P; Meeran SM
Adv Exp Med Biol; 2019; 1152():293-310. PubMed ID: 31456191
[TBL] [Abstract][Full Text] [Related]
12. Treatment of cardiovascular pathology with epigenetically active agents: Focus on natural and synthetic inhibitors of DNA methylation and histone deacetylation.
Chistiakov DA; Orekhov AN; Bobryshev YV
Int J Cardiol; 2017 Jan; 227():66-82. PubMed ID: 27852009
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic therapy for breast cancer.
Cai FF; Kohler C; Zhang B; Wang MH; Chen WJ; Zhong XY
Int J Mol Sci; 2011; 12(7):4465-87. PubMed ID: 21845090
[TBL] [Abstract][Full Text] [Related]
14. Quercetin modifies 5'CpG promoter methylation and reactivates various tumor suppressor genes by modulating epigenetic marks in human cervical cancer cells.
Kedhari Sundaram M; Hussain A; Haque S; Raina R; Afroze N
J Cell Biochem; 2019 Oct; 120(10):18357-18369. PubMed ID: 31172592
[TBL] [Abstract][Full Text] [Related]
15. Remodeling epigenetic modifications at tumor suppressor gene promoters with bovine oocyte extract.
Wang Z; Yue Y; Han P; Sa R; Ren X; Wang J; Bai H; Yu H
Cytotherapy; 2013 Sep; 15(9):1164-73. PubMed ID: 23800731
[TBL] [Abstract][Full Text] [Related]
16. Direct monitoring of breast and endometrial cancer cell epigenetic response to DNA methyltransferase and histone deacetylase inhibitors.
Teixeira SR; Abreu CM; Parkes L; Davies J; Yao S; Sawhney MA; Margarit L; Gonzalez D; Pinto IM; Francis LW; Conlan RS
Biosens Bioelectron; 2019 Sep; 141():111386. PubMed ID: 31220725
[TBL] [Abstract][Full Text] [Related]
17. Reversal of epigenetic aberrations associated with the acquisition of doxorubicin resistance restores drug sensitivity in breast cancer cells.
Ponnusamy L; Mahalingaiah PKS; Chang YW; Singh KP
Eur J Pharm Sci; 2018 Oct; 123():56-69. PubMed ID: 30016648
[TBL] [Abstract][Full Text] [Related]
18. Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts.
Gozzini A; Santini V
Ann Hematol; 2005 Dec; 84 Suppl 1():54-60. PubMed ID: 16228241
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic therapy in non-small-cell lung cancer: targeting DNA methyltransferases and histone deacetylases.
Vendetti FP; Rudin CM
Expert Opin Biol Ther; 2013 Sep; 13(9):1273-85. PubMed ID: 23859704
[TBL] [Abstract][Full Text] [Related]
20. Natural Agents-Mediated Targeting of Histone Deacetylases.
Farooqi AA; Naqvi SK; Perk AA; Yanar O; Tabassum S; Ahmad MS; Mansoor Q; Ashry MS; Ismail M; Naoum GE; Arafat WO
Arch Immunol Ther Exp (Warsz); 2018 Feb; 66(1):31-44. PubMed ID: 28852775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
